PainChek Strengthens US Expansion with AU$5.5 million Funding Boost
PainChek Limited (ASX: PCK) has secured AU$5.5 million through unsecured convertible notes to accelerate its expansion across the United States and strengthen working capital. The funding was supported by a group of existing professional and sophisticated investor-shareholders, reflecting continued confidence in the company’s long-term growth strategy. The notes carry a 12-month maturity period with a conversion price of AU$0.195 per share and a 12% annual interest rate payable monthly.
The company plans to utilise the proceeds to expand sales and marketing initiatives in North America while improving overall trading performance and operational efficiency. Management highlighted that the financing comes at a strategic time following PainChek’s agreement covering 350 US aged care homes and growing opportunities linked to Remote Therapeutic Monitoring reimbursement pathways.
PainChek continues to strengthen its position in AI-powered pain assessment solutions, with its technology already adopted across more than 2,000 aged care facilities globally and over 20 million digital pain assessments completed to date.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
PainChek Strengthens US Expansion with AU$5.5 million Funding Boost
PainChek Limited (ASX: PCK) has secured AU$5.5 million through unsecured convertible notes to accelerate its expansion across the United States and strengthen working capital. The funding was supported by a group of existing professional and sophisticated investor-shareholders, reflecting continued confidence in the company’s long-term growth strategy. The notes carry a 12-month maturity period with a conversion price of AU$0.195 per share and a 12% annual interest rate payable monthly.
The company plans to utilise the proceeds to expand sales and marketing initiatives in North America while improving overall trading performance and operational efficiency. Management highlighted that the financing comes at a strategic time following PainChek’s agreement covering 350 US aged care homes and growing opportunities linked to Remote Therapeutic Monitoring reimbursement pathways.
PainChek continues to strengthen its position in AI-powered pain assessment solutions, with its technology already adopted across more than 2,000 aged care facilities globally and over 20 million digital pain assessments completed to date.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au